Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;93(3):446-459.
doi: 10.1002/ana.26550. Epub 2023 Jan 2.

A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease

Maria Ilenia De Bartolo #  1 , Giorgio Vivacqua #  2   3 , Daniele Belvisi  1   4 , Romina Mancinelli  3 , Andrea Fabbrini  4 , Nicoletta Manzo  4   5 , Matteo Costanzo  1 , Giorgio Leodori  1   4 , Antonella Conte  1   4 , Giovanni Fabbrini  1   4 , Sergio Morini  2 , Alfredo Berardelli  1   4
Affiliations

A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease

Maria Ilenia De Bartolo et al. Ann Neurol. 2023 Mar.

Abstract

Objective: To investigate molecular biomarkers of a-synuclein and tau aggregation, autophagy, and inflammation in the saliva of de novo Parkinson's disease (PD) patients in comparison to healthy subjects (HS), and to correlate molecular data with clinical features of PD patients, in order to establish whether abnormalities of these parameters are associated with specific clusters of de novo PD patients, and their potential diagnostic power in differentiating PD patients from HS.

Methods: We measured total and oligomeric a-synuclein, total-tau and phosphorylated-tau, microtubule-associated protein light chain 3 beta (MAP-LC3beta), and tumor necrosis factor alpha (TNFalpha) in the saliva of 80 de novo PD patients and 62 HS, using quantitative enzyme-linked immunosorbent Assay analysis.

Results: Oligomeric a-synuclein, total-tau, MAP-LC3beta, and TNFalpha levels resulted significantly higher in patients with respect to HS, while no significant differences were detected for total a-synuclein or phosphorylated-tau. Phosphorylated-tau directly correlated with MAP-LC3beta, whereas it inversely correlated with TNFalpha in PD patients. An inverse correlation was detected between MAP-LC3beta and non-motor symptoms severity. Principal Component Analysis showed that molecular and clinical parameters were independent of each other in de novo PD patients. Receiver operating characteristic curve analysis reported an accurate diagnostic performance of oligomeric a-synuclein and MAP-LC3beta. The diagnostic accuracy of total a-synuclein increased when it was combined with other salivary biomarkers targeting different molecular pathways.

Interpretation: Our study proposes a novel biomarker panel using saliva, a non-invasive biofluid, in de novo PD patients, with implications in understanding the molecular pathways involved in PD pathogenesis and the relevance of different molecular pathways in determining clinical PD subtypes. ANN NEUROL 2023;93:446-459.

PubMed Disclaimer

References

    1. Spillantini MG, Schmidt ML, Lee VM-Y, et al. α-Synuclein in Lewy bodies [internet]. Nature 1997;388:839-840.
    1. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014;137:1496-1513.
    1. Wood SJ, Wypych J, Steavenson S, et al. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;274:19509-19512.
    1. Kruse N, Mollenhauer B. Quantification of alpha-Synuclein in biological fluids by Electrochemiluminescence-based detection. In: Bartels T, ed. Alpha-Synuclein. Springer New York: New York, NY, 2019:59-68.
    1. Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol 2019;18:573-586.

LinkOut - more resources